CSL vs RARE · P/E 21, rev $2.62B vs rev $350.0M
Carlisle Companies Incorporated (CSL) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Carlisle Companies Incorporated (CSL) is a building products & equipment company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported CSL revenue for 2026-06-30 was $2.62B. Net income was $382.9M. CSL currently screens at market cap $16.31B and trailing P/E 21.0.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
CSL currently screens at market cap $16.31B and trailing P/E 21.0. RARE currently screens at market cap $2.79B.
Not investment advice. Open the CSL and RARE stock pages for the full models.
Not investment advice.